Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies

Date

23 Nov 2019

Session

Poster display session

Topics

Immunotherapy

Tumour Site

Presenters

Esdy Rozali

Citation

Annals of Oncology (2019) 30 (suppl_9): ix107-ix114. 10.1093/annonc/mdz438

Authors

E. Rozali1, C.L. Chiang1, P.W. Wang1, H.C. Toh2

Author affiliations

  • 1 Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG
  • 2 Medical Oncology, NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 326P

Background

Analysis of ∼18,000 human tumors across 39 cancers identified tumor infiltrating γδ T cells as the most favorable prognostic immune population. Sharing both innate and adaptive immune properties, γδ T cells are an attractive candidate for direct adoptive cellular therapy as well as utilizing their professional antigen presenting cell (APC) property for ex vivo expansion of antigen-specific CD4+and CD8+ T cells for subsequent adoptive cellular therapy.

Methods

Here, we report a Good Manufacturing Method (GMP) expansion protocol of Vγ9Vδ2 T cells from human PBMCs and its functional and transcriptomic characterization.

Results

Following cytokine optimization experiments, we found that some combinations of IL-2, IL-15 and IL-21 led to optimal antigen presentation and effector functions. γδ T cells produced in the presence of IL-2 alone or in combination with other cytokines showed increased APC markers compared to IL-15 combinations. In vitro, EBV-LMP2 peptide-pulsed γδ T cells primed a more robust naïve CD3+ T cell proliferation than monocyte-derived Dendritic Cells (moDC). Importantly, EBV-LMP2 peptide-pulsed γδ T cells stimulated less T regulatory cells and exhausted CD8+ and CD4+ T cells compared to moDCs.Through gene expression profiling, we demonstrated that γδ T cells express enhanced levels of markers of cross presentation pathway compared to moDCs which may explain the cross presentation phenotype. Finally, we demonstrated the potential of EBV-LMP2 peptide-pulsed Vγ9Vδ2 T cells as a therapeutic cancer vaccine in an autologous EBV-lymphoblastoid cell line tumor model in vivo. This therapeutic intervention resulted in increased tumor infiltration of gd, CD8+ and CD4+ T cells and improved control of primary tumor growth and metastasis of EBV LCLs tumor model in vivo.

Conclusions

In summary, we demonstrated in our pre-clinical study γδ T cell APC and effector functions in vitro and in vivo, indicating the potential of γδ T cells as therapeutic immunotherapy against EBV-positive cancers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Tessa Therapeutics.

Disclosure

P.W.-W. Wang: Advisory / Consultancy: Tessa Therapeutics. H.C. Toh: Leadership role, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: Tessa Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.